Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024

Humacyte, Inc.

Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.
Phase 3 V007 AV access trial: 238 of 240 patients enrolled; topline results one year after enrollment completion.
Cash, equivalents & short-term investments: $151.9M at Dec 31, 2022, down from $225.5M; runway through end 2024.
Q4 2022 net loss $3.7M vs net income $42.6M in Q4 2021; full-year net loss $12.0M vs $26.5M in 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Humacyte, Inc. reported financial results for fiscal fourth quarter and full year ended December 31, 2022.

Period: fiscal fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 24, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.